Alkermes Appoints Caroline J. Loew

Alkermes Appoints Caroline J. Loew, Ph.D., as Chief Executive ...

Loew , Ph.D., has been appointed as the chief executive officer designate of Mural Oncology plc (Mural Oncology), the new independent public ...

Alkermes Appoints Caroline J. Loew, Ph.D., as Chief Executive ...

PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that Caroline J. Loew, Ph.D., has been appointed as the chief executive officer ...

Alkermes Appoints Caroline J. Loew, Ph.D., as Chief Executive ...

Alkermes Appoints Caroline J. Loew, Ph.D., as Chief Executive Officer Designate of Mural Oncology plc · Massive Rivian Update: Georgia Timeline and a $10 Billion ...

Alkermes Appoints Caroline J. Loew, Ph.D., as Chief Executive Of

PR Newswire DUBLIN, June 1, 2023 — Dr. Loew to Assume New Leadership Role Upon Completion of the Planned Separation of Alkermes' Oncology Business — —

Alkermes Appoints Caroline J. Loew, Ph.D., as Chief Executive ...

... alkermes-appoints-caroline-j-loew-phd-a…

— Dr. Loew to Assume New Leadership Role Upon Completion of the Planned Separation of Alkermes' Oncology ...

Alkermes To Spin-Off Mural Oncology In 2H23 - Forbes

On 6/1, Alkermes announced the appointment of Caroline J. Loew, Ph.D., as the CEO designate of Mural Oncology plc. Dr. Loew has joined Alkermes ...

Alkermes plc Reports Second Quarter 2023 Financial Results

June 2023 , Alkermes appointed Caroline J. Loew, Ph.D., as the chief executive officer designate of Mural Oncology plc (Mural Oncology), the new independent ...

Why a former BMS exec calls her new CEO role 'unfinished ...

Caroline Loew explains how she's building a new company culture at an Alkermes spinoff — and a pipeline that offers a next-gen approach to ...

Alkermes plc completed the spin-off of Mural Oncology plc for ...

... Alkermes' oncology business. Caroline J. Loew appointed as the chief executive officer designate of Mural Oncology plc. Richard Pops will ...

Alkermes picks Loew to lead oncology spinout - BioCentury

Alkermes plc (NASDAQ:ALKS) named Caroline Loew as CEO designate of Mural Oncology plc, the new public company into which Alkermes is ...

Alkermes to Participate in Two Upcoming Investor Conferences

Alkermes Appoints Caroline J. Loew, Ph.D., as Chief Executive Officer Designate of Mural Oncology plc. Image for Alkermes Appoints Caroline J.

Alkermes plc Reports Second Quarter 2023 Financial Results

- In June 2023, Alkermes appointed Caroline J. Loew, Ph.D., as the chief executive officer designate of Mural Oncology plc (Mural Oncology) ...

Alkermes plc Reports Second Quarter 2023 Financial Results

- In June 2023, Alkermes appointed Caroline J. Loew, Ph.D., as the chief executive officer designate of Mural Oncology plc (Mural Oncology) ...

People | Nature Biotechnology

People · Caroline J. Loew · Kate McKinley has been appointed chief business officer of clinical-stage Rani Therapeutics. · Cindy Perettie has ...

Amendment: SEC Form SC 13G/A filed by Alkermes plc - Quantisnow

Alkermes Appoints Caroline J. Loew, Ph.D., as Chief Executive Officer Designate of Mural Oncology plc. Image for Alkermes Appoints Caroline J.

Glympse Bio, Inc. Appoints Caroline J Loew, Ph.D. President and ...

Appoints Caroline J Loew, Ph.D. President and Chief Executive Officer. Stanley Lapidus appointed as Chairman of the Board; Dr. Robert Langer ...

Caroline J Loew, PhD - Cambridge, Massachusetts, United States

Location: Cambridge · 500+ connections on LinkedIn. View Caroline J Loew, PhD's profile on LinkedIn, a professional community of 1 billion members.

生物制药公司Alkermes宣布任命Caroline J. Loew博士为Mural ...

2023年6月1日，生物制药公司Alkermes plc宣布Caroline J. Loew博士已被任命为Mural Oncology plc的候任首席执行官，该公司是Alkermes肿瘤业务计划分离后 ...

Sitemap ALKS News - Stock Titan

... Alkermes for the Benefit of Shareholders Alkermes Appoints Caroline J. Loew, Ph.D., as Chief Executive Officer Designate of Mural Oncology plc Alkermes ...

Caroline J. Loew - MURA | Mural Oncology PLC - Wall Street Journal

Caroline J. Loew holds the position of Chief Executive Officer, Secretary & Director at Mural Oncology Plc.